Introduction
CUP is a common disease with an incidence of 3-5% among other epithelial tumors. Worldwide the overall age-standardized incidence per 100.000 people per year is ranging between 4-19 cases. It is characterized as a metastatic cancer diagnosed without the primary site, despite histopathological and radiological laboratory investigations. The median age at diagnosis is 60 years with a male predilection [1] .
Today, the definition of CUP includes patients who present with histologically-confirmed metastatic cancer in whom a detailed medical history, complete physical examination including pelvic and rectal examination, full blood count and biochemistry, urinalysis and stool occult blood testing, histopathological review of biopsy material with the use of immunohistochemistry, chest radiography, computed tomography (CT) of the abdomen and pelvis and, in certain cases, mammography and PET scan fail to identify the primary site [1] .
Biology of CUP
CUP's biology is poorly understood although several molecular or translational research studies are available. One hypothesis postulates that CUP does not undergo type 1 progression (from a premalignant lesion to malignant) but instead it follows a type 2 progression without forming a primary site. A second hypothesis supports that CUP follows the parallel progression model, where metastases can arise early in the development of a malignant process [2, 3] .
Several research data have shown that CUP rarely harbors activating point mutations in either oncogenes or tumor suppressor genes, has active angiogenesis in 50-80%, overexpress various oncogenes in 10-30%, hypoxia-related proteins in 25%, epithelial-mesenchymal transition markers in 16% and have activated intracellular signaling axes such as AKT or MAPK in 20-35% [4] [5] [6] (Table 1) . Very recently global microRNA profiling showed no significant expression differences with metastases of matched known primary tumors failing to identify any specific ''CUP signature'' [7, 8] .
Clinicopathological subsets
CUP is associated with a short history of symptoms and signs, has an early dissemination with an aggressive behavior in most of the times (three or more organs are involved) and often carries unpredictable metastatic patterns. Unpredictable metastatic pattern at diagnosis refers to the differences in the incidence of metastatic sites between known and unknown primary carcinomas i.e. pancreatic cancer presenting as CUP has 4-fold higher incidence to affect bones, and 30% incidence to appear with lung metastases in contrast to the known natural history of known primary pancreatic cancer.
To search the primary site a number of investigations are required including clinical data, immunohistochemistry studies, blood tests, radiological techniques and endoscopic procedures [1] . Table 2 indicates the necessary investigations that should be performed in suspected CUP cases.
Since 2003 CUP is divided into two separated groups the favorable (20%) and the unfavorable (80%) group [9] . Favorable subsets are those entities that respond to local and/or systemic treatments and have a longer survival. Table 3 demonstrates the classification of CUP patients into various clinicopathological subsets.
Woman with adenocarcinoma involving axillary nodes
This is a CUP subset in which the primary site is most often hidden in the breasts. It has a presentation similar to breast cancer of stage II (N 2 or N 3 disease), and it affects exclusively women of a mean age of 52 years. The most frequent histology is ductal adenocarcinoma. Forty percent have positive estrogen receptors. After undergoing mastectomy, almost 70% of the patients have an occult breast primary identified [10] .
Women with papillary adenocarcinoma of peritoneal cavity
This entity has also been called primary peritoneal carcinoma. Clinical presentation includes pain, ascites, abdominal masses or intestinal obstruction. Median age is 60 years. Histopathology is always compatible with serous papillary adenocarcinoma with or without psammoma bodies. Immunohistochemical expression of MUC10, estrogen receptors, mesothelin, WT1 and KRT7 can be found. Serum CA 125 is very often raised.
In comparison with primary ovarian cancer, primary peritoneal carcinoma affects older women, has more bulky disease and has more overexpression of HER 2 oncogene and Ki67 [11] .
Squamous cell carcinoma involving cervical nodes
It is more frequent in men (80%) with a median age of 60 years and it constitutes 5% of all head and neck cancers. Clinical presentation includes a painless and unilateral cervical mass, most commonly affecting Level II lymph nodes (jugulodigastric or upper nodes). Fine needle aspiration has a diagnostic Table 4 Immunohistochemistry tests for investigating CUP.
Diagnosis
Step one AE1 or AE3 pan-cytokeratin Carcinoma Common leukocyte antigen Lymphoma S100; HMB-45 Melanoma S100; vimentin Sarcoma
Step two CK7 or CK20;PSA Adenocarcinoma PLAP; OCT4; AFP; human chorionic gonadotropin Germ-cell tumor Hepatocyte paraffin 1; canalicular pCEA, CD10, or CD13 Hepatocellular carcinoma RCC; CD10
Renal cell carcinoma TTF1; thyroglobulin Thyroid carcinoma Chromogranin; synaptophysin; PGP9.5; CD56
Neuroendocrine carcinoma CK5 or CK6; p63
Squamous cell carcinoma
Step three PSA; PAP Prostate TTF1 Lung GCDFP-15; mammaglobin; ER Breast CDX2; CK20 Colon CDX2 (intestinal epithelium); CK20; CK7 Pancreas or biliary ER; CA-125; mesothelin, WT1 Ovary accuracy of almost 95%. A panendoscopy with biopsy should follow. Radiology is very helpful with a sensitivity of CT-scan in 22%, MRI in 36% and PET-scan up to 60% [12] .
Poorly differentiated neuroendocrine carcinoma
It represents the 90% of CUP neuroendocrine tumors, the rest being of well differentiated low grade histology. It affects males (65%) of a median age of 65 years. Retroperitoneal, mediastinal or peripheral lymph nodes are the most common dominant sites (40%) following by liver (25%) and bones (10-15%) [13] .
Recently, neuroendocrine Merkel cell nodal carcinoma of stage IIIB has been recognized as having also a long-term survival [14] .
Adenocarcinoma with a colon-profile (CK20 + , CK7 À , CDX2 + ) Up to now less than 100 cases have been reported mostly in women, with a median age of 57 years. Disease is extended in the abdomen involving abdominal nodes in 51%, peritoneal surfaces in 50%, liver in 30% and ascites in 27% [15, 16] .
Unfavorable subsets metastatic visceral or skeletal CUP
These are the most frequent subsets of CUP. They have a poor prognosis with a short survival. The most common histological types are adenocarcinomas of moderate to poorly differentiated (64%), the rest been undifferentiated tumors. It involves mainly the liver in 40-50% of the cases, followed by lymph nodes (35%), lungs (31%), bones (28%) and the brain (15%) [1, 9] .
Searching for the primary

Pathology and immunohistochemistry
Histopathology is one the most important avenue in the elaboration of CUP diagnosis. Immunohistochemistry with a wide battery of staining (including cytokeratins), is of a great value since it could differentiate between: (a) carcinoma, sarcoma or lymphoma, (b) adenocarcinoma, germ-cell tumor, hepatocellular, renal, thyroid, neuroendocrine or squamous carcinomas as well as (c) the primary site of an adenocarcinoma (lung, breast, ovarian, prostate, colon, pancreas or biliary cancer) (Tables 4  and 5 ) [17] .
Molecular diagnosis
During the last decade commercial tests of gene profiling microarrays became available for the diagnosis of CUP. Assays on cDNA or miRNA platforms gave accuracy rates up to 93% in detecting the primary site and could probably allow particular and specific therapeutic management in CUP patients [18, 19] . Whether this promising technology will lead us to better patients' outcome, it remains uncertain. A number of clinical trials are still ongoing.
Radiology
Over the past 30 years CT scan, MRI and PET-scan added substantially to the detection of primary site. CT scans provided a diagnostic accuracy of 55% (36-74%) mainly in pancreatic, colorectal and lung cancer, while MRI was found to be very sensitive in detecting primary breast cancers in 70% of cases [1] . Fluorodeoxyglucose (FDG) PET accuracy in CUP ranges between 25% and 43%. The most common primary sites detected by PET are lung cancer (33%), head and neck cancers (27%), followed by pancreatic, breast and colon cancers (4-5%).
68 Ga-DOTA-NOC receptor PET/CT is also very accurate in identifying primary neuroendocrine tumors or their metastatic lesions [20, 21] .
Endoscopy
Endoscopies in general, carry low accuracy rates and low sensitivity and specificity. Endoscopies should not be used in all CUP patients for the detection of primary site, unless they are clinically presenting with relevant symptoms and signs or in patients with specific histopathological findings. A colonoscopy should be requested in CK7 + , CK20 + and CDX2 + cases or bronchoscopy in CK7 + and TTF1 + patients [1] .
Serum tumor markers
Elevated epithelial serum tumor markers can be overexpressed in CUP patients. In almost 70% of them two or three markers can be concomitantly increased in a non-specific way. CA-125, CA-15-3, CA19-9, CEA can be raised without any diagnostic, prognostic or predictive value. Therefore, routine request of these tumor markers is not recommended. However, in specific cases it might offer diagnostic aid such as serum prostate-specific antigen in men with osteoblastic bone metastases, CA125 in females with primary serous papillary peritoneal adenocarcinoma, or CA 15-3 in women with isolated axillary adenocarcinoma [22] .
Molecular diagnosis
During the last ten years gene-expression profiling in the classification and detection of primary tumor sites has led to the development of commercially available tests. The accuracy rates of these tests are up to 90% but its validity in daily practice remains uncertain. Randomized prospective studies are needed to establish whether patients' outcomes are improved by its clinical use.
It should be added here, that the frequency of detecting the primary site by all conventional investigations antemortem is around 30% (excluding gene profiling techniques) whereas from the postmortem studies the detection could be up to 70% [9] .
Therapeutic management (Table 6) Women with adenocarcinoma involving axillary nodes These patients should be treated with complete axillary dissection, ipsilateral breast radiotherapy followed by adjuvant chemotherapy and/or hormonotherapy depending on the risk factors. Patients without local treatment are associated with high locoregional relapse rates (40-55%). Survival is longer in patients who received primary breast radiotherapy as well as in patients with adjuvant systemic treatment [1, 10] .
Women with papillary adenocarcinoma of peritoneal cavity
Patients with primary peritoneal adenocarcinoma should be treated similarly to stage III and IV ovarian cancer. Surgical cytoreduction followed by platinum and paclitaxel chemotherapy is the treatment of choice. Median response rate is 80% with 30-40% complete responders and a median survival of 36 months. Some reports have demonstrated poorer survival of patients with primary peritoneal carcinoma as compared to primary ovarian cancer due to reasons depicted in the section of clinicopathological entities [1, 11] . 
Squamous cell carcinoma involving cervical nodes
Patients with N 1 or N 2a disease without extra capsular extension could be treated with surgery alone including excisional biopsy, radical or modified radical neck dissection, and/or bilateral tonsillectomy. Locoregional control is around 80-90% and 5-year overall survival up to 65%. Postoperative radiotherapy is indicated in excisional or incisional biopsy, extracapsular extension, stage N 2b or higher, in fixed nodes to the adjacent structure or in patients with low performance status and comorbidities. The irradiation fields include the involved nodal stations (65-70 Gy), the uninvolved sites (50 Gy) and the mucosal sites (50-60 Gy).
Chemoradiation could be indicated in N2 or N3 cases with cisplatin based chemotherapy. Chemoradiation could be associated with significant grade 3 toxicities [1, 12] .
Poorly differentiated neuroendocrine carcinomas
This group of patients should be treated with platinum-based or platinum-taxane combination chemotherapy. Response rates are up to 55% with 20% complete responders and overall survival of 15 months and almost 10-15% long-term survivors [1, 13] .
Adenocarcinoma with a colon-profile (CK20 + , CK7
This subset of patients should be treated as advanced colorectal cancer cases. Overall response rate is 50% with 15% complete and 35% partial responses and median survival of 21-37 months [1, 15, 16] .
Other favorable subsets
Patients with metastatic bone metastases and elevated serum PSA should be managed as advanced prostate cancer [1] . Patients with isolated inguinal nodal metastases or a single metastatic lesion should undergo local dissection with or without local radiotherapy [1] .
Treatment of unfavorable subsets
Unfortunately, this group of CUP patients represents the 80% of the cases. They are usually treated with empirical chemotherapy mostly with platinum or taxane combinations. Response rates are around 20% and median survival of six months (Fig. 1) . A recent meta-analysis has shown that no type of chemotherapy has demonstrated any survival benefit in these subsets [23, 24] . Specific targeted treatment in CUP patients following gene profiling microarray tests has not yet been proven. Since there are no prospective randomized studies available, we have to wait until some already ongoing trials appear. Table 6 summarizes therapeutic options according to the ESMO guidelines [25] and Table 7 the prognostic features of favorable subsets. Finally, Table 8 provides an algorithm of searching the primary site and treating CUP patients accordingly.
Conclusions
CUP is a well recognized clinical syndrome and may be defined as a disease with early disease dissemination without a primary detected site. It could have a favorable or unfavorable out- 
